TrialRMD open2021

Efficacy and safety of tofacitinib modified-release 11 mg once daily plus methotrexate in adult patients with rheumatoid arthritis: 24-week open-label phase results from a phase 3b/4 methotrexate withdrawal non-inferiority study (ORAL Shift).

Stanley B Cohen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.